Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients

Liver Transplantation

Volumn 18, Issue 9, 2012, Pages 1093-1099

  Bodro, Marta ^a   Sabé, Núria ^a   Lladõ, Laura ^a   Baliellas, Carme ^a   Niubõ, Jordi ^a   Castellote, Jose ^a   Fabregat, Joan ^a   Rafecas, Antoni ^a   Carratalã, Jordi ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; STEROID; VALGANCICLOVIR; VIRUS ANTIGEN;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GANCICLOVIR; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865612420     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23460     Document Type: Article

References (36)

1. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG,. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997; 126: 275-279. (Pubitemid 27078775)
2. Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 1998; 66: 1020-1028. (Pubitemid 28513381)
3. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614. (Pubitemid 350294226)
4. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105-2115. (Pubitemid 40826968)
5. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854-860. (Pubitemid 34274427)
6. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880. (Pubitemid 46202222)
7. Razonable RR,. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14: 4849-4860.
8. Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, et al.; for RESITRA. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008; 46: 20-27. (Pubitemid 351263554)
9. Torre-Cisneros J, Madueño JA, Herrero C, de la Mata M, Gonzalez R, Rivero A, et al. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 2002; 8: 773-780. (Pubitemid 36054279)
10. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143. (Pubitemid 44199547)
11. Strippoli GF, Hodson EM, Jones C, Craig JC,. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139-145.
12. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652. (Pubitemid 43948296)
13. de la Torre-Cisneros J, Fariñas MC, Castõn JJ, Aguado JM, Cantisán S, Carratalá J, et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29: 735-758.
14. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al.; for Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
15. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F,. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983. (Pubitemid 351537752)
16. Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antõn A, et al. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Transplant Proc 2007; 39: 2228-2230. (Pubitemid 47418194)
17. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV,. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85-90. (Pubitemid 40140005)
18. Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus- seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 2008; 14: 240-244. (Pubitemid 351267283)
19. Singh N,. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16: 281-287. (Pubitemid 44497309)
20. Singh N,. Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients. Transplantation 2011; 91: 825-826.
21. Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, Limaye AP,. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis 2011; 13: 244-249.
22. Meylan PR, Manuel O,. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007; 20: 412-418. (Pubitemid 47026240)
23. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR,. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13: 1703-1709.
24. Humar A, Michaels M,; for AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274. (Pubitemid 43382161)
25. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097. (Pubitemid 34289682)
26. Sun HY, Wagener MM, Singh N,. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8: 2111-2118.
27. Small LN, Lau J, Snydman DR,. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869-880. (Pubitemid 44435514)
28. Sun HY, Cacciarelli TV, Wagener MM, Singh N,. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients. Transpl Immunol 2010; 23: 166-169.
29. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, Martín-Peña A, Sanchez B, Martin-Gandul C, et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 2011; 91: 927-933.
30. Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, et al. High incidence of anticytomegalovirus drug resistance among D+/R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012; 12: 202-209.
31. Fishman JA,. Prophylaxis, preemption and drug resistance in CMV infection: too little, too much or just right? Am J Transplant 2012; 12: 13-14.
32. San Juan R, Yebra M, Lumbreras C, Lõpez-Medrano F, Lizasoain M, Meneu JC, et al. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. Clin Transplant 2009; 23: 666-671.
33. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
34. Kalil AC, Sun J, Florescu DF,. IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis. Am J Transplant 2011; 11: 18-21.
35. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427-1431.
36. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214-1222.